The public relations team at Children’s Healthcare of Atlanta is available to assist the news media by providing story ideas, experts, breaking news, background information and patient stories about the Aflac Cancer Center and Blood Disorders Service.
To protect the privacy rights of patients and their families, a representative of the public relations team must accompany any member of the news media visiting our hospitals or satellite offices.
In the News
For a list of current news stories about the Aflac Cancer Center, visit our "In the News"
Did You Know?
- The Aflac Cancer Center is recognized as one of the top cancer centers in the country by U.S.News & World Report. We offer access to cutting edge advanced surgical and diagnostic radiology services as well as multidisciplinary comprehensive care in the areas of neuro-oncology, sarcoma, survivorship, sickle cell disease, hemophilia, and blood and marrow transplants.
- Physicians and staff hold national leadership positions on more than 18 different organizations, including the President’s National Cancer Advisory Board, Children’s Oncology Group, Hemophilia Research Society and Novel Molecular Therapies for Childhood Cancer.
- The Aflac Cancer Center performs an average of 50 blood and marrow transplants each year.
- The Aflac Cancer Center achieved blood and marrow transplant day 100 mortality rates for both autologous (donation from oneself) and allogeneic (donor with genetically different but compatible genes) transplants that are lower than the national average.
- With a continued focus on clinical and laboratory quality, the Blood and Marrow Transplant (BMT) Program was awarded accreditation in 2005 by the Foundation for the Accreditation of Cellular Therapy (FACT). The Aflac Cancer Center is the only FACT-accredited pediatric center in Georgia.
- Aflac financial support of more than $60 million has facilitated the growth and development of the Aflac Cancer Center’s scientific and research initiatives as well as expansion of clinical programming.
- Based on data from the Children’s Oncology Group, the Aflac Cancer Center ranks among the leading centers in the country for number of patients on therapeutic clinical trials for pediatric cancer. This top ranking illustrates our position as one of the nations leading centers conducting clinical research in the treatment of pediatric cancer.
- The Aflac Cancer Center has performed more blood and marrow transplants for sickle cell disease than any other program in the country, including the first successful unrelated cord blood transplant for sickle cell disease.
- The Aflac Cancer Center offers the largest comprehensive pediatric sickle cell disease program in the country, serving more than 1,600 children with sickle cell disease at three hospital campuses in metro Atlanta.
- The comprehensive hemophilia program at Emory University School of Medicine and the Aflac Cancer Center is the largest program in the country to have a unique partnership between a healthcare provider and a non-profit organization, Hemophilia of Georgia. This partnership with Hemophilia of Georgia provides significant funding and other resources to allow Emory and the Aflac Cancer Center to deliver cutting-edge patient care, educate providers and conduct innovative research in pediatric and adult hemophilia and bleeding disorders.
Peter Lollar, M.D., a researcher at the Aflac Cancer Center, has developed the first recombinant non-human FV-III molecule, now undergoing clinical trials at sites around the country, including Children’s. In recognition of his significant work to achieve advances in hemophilia treatment, Dr. Lollar was awarded an endowed chair by Hemophilia of Georgia to serve as Director of Hemostasis Research for Emory and the Aflac Cancer Center.
William G. Woods, M.D., Director of the Aflac Cancer Center, served as president of the American Society of Pediatric Hematology/Oncology (ASPH/O) in 2006-2008. ASPH/O is the leading national professional society of pediatric hematologists/oncologists, physicians dedicated to the clinical care and research of childhood cancer and blood disorders.